Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt 0.92
BMRN's Cash to Debt is ranked lower than
80% of the 858 Companies
in the Global Biotechnology industry.

( Industry Median: 68.31 vs. BMRN: 0.92 )
Ranked among companies with meaningful Cash to Debt only.
BMRN' s 10-Year Cash to Debt Range
Min: 0.12  Med: 1.16 Max: No Debt
Current: 0.92
Equity to Asset 0.65
BMRN's Equity to Asset is ranked lower than
54% of the 616 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. BMRN: 0.65 )
Ranked among companies with meaningful Equity to Asset only.
BMRN' s 10-Year Equity to Asset Range
Min: -0.66  Med: 0.57 Max: 0.97
Current: 0.65
-0.66
0.97
F-Score: 3
Z-Score: 9.93
M-Score: -1.66
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) -20.62
BMRN's Operating margin (%) is ranked higher than
61% of the 675 Companies
in the Global Biotechnology industry.

( Industry Median: -71.95 vs. BMRN: -20.62 )
Ranked among companies with meaningful Operating margin (%) only.
BMRN' s 10-Year Operating margin (%) Range
Min: -1075  Med: -29.30 Max: 13.41
Current: -20.62
-1075
13.41
Net-margin (%) -24.59
BMRN's Net-margin (%) is ranked higher than
59% of the 675 Companies
in the Global Biotechnology industry.

( Industry Median: -68.66 vs. BMRN: -24.59 )
Ranked among companies with meaningful Net-margin (%) only.
BMRN' s 10-Year Net-margin (%) Range
Min: -1025  Med: -32.15 Max: 54.7
Current: -24.59
-1025
54.7
ROE (%) -11.41
BMRN's ROE (%) is ranked higher than
65% of the 775 Companies
in the Global Biotechnology industry.

( Industry Median: -30.76 vs. BMRN: -11.41 )
Ranked among companies with meaningful ROE (%) only.
BMRN' s 10-Year ROE (%) Range
Min: -751.65  Med: -14.97 Max: 39.6
Current: -11.41
-751.65
39.6
ROA (%) -7.26
BMRN's ROA (%) is ranked higher than
68% of the 864 Companies
in the Global Biotechnology industry.

( Industry Median: -26.75 vs. BMRN: -7.26 )
Ranked among companies with meaningful ROA (%) only.
BMRN' s 10-Year ROA (%) Range
Min: -76.62  Med: -8.96 Max: 18.88
Current: -7.26
-76.62
18.88
ROC (Joel Greenblatt) (%) -24.89
BMRN's ROC (Joel Greenblatt) (%) is ranked higher than
67% of the 833 Companies
in the Global Biotechnology industry.

( Industry Median: -365.20 vs. BMRN: -24.89 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
BMRN' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -433  Med: -43.07 Max: 31.1
Current: -24.89
-433
31.1
Revenue Growth (3Y)(%) 9.20
BMRN's Revenue Growth (3Y)(%) is ranked higher than
64% of the 411 Companies
in the Global Biotechnology industry.

( Industry Median: 0.30 vs. BMRN: 9.20 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
BMRN' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0  Med: 9.60 Max: 97.7
Current: 9.2
0
97.7
EPS Growth (3Y)(%) 24.20
BMRN's EPS Growth (3Y)(%) is ranked higher than
80% of the 420 Companies
in the Global Biotechnology industry.

( Industry Median: -6.80 vs. BMRN: 24.20 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
BMRN' s 10-Year EPS Growth (3Y)(%) Range
Min: 0  Med: -0.95 Max: 36.5
Current: 24.2
0
36.5
» BMRN's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2014

BMRN Guru Trades in Q3 2014

Paul Tudor Jones 5,913 sh (New)
Joel Greenblatt 3,885 sh (New)
Steven Cohen 675,600 sh (+649.83%)
Manning & Napier Advisors, Inc 288,180 sh (+18.08%)
John Griffin 2,230,000 sh (+6.19%)
Frank Sands 12,098,628 sh (+1.45%)
PRIMECAP Management 8,043,918 sh (-0.25%)
Columbia Wanger 853,800 sh (-26.89%)
» More
Q4 2014

BMRN Guru Trades in Q4 2014

Louis Moore Bacon 56,100 sh (New)
RS Investment Management 94,400 sh (New)
Frank Sands 12,183,113 sh (+0.70%)
Frank Sands 12,183,113 sh (+0.70%)
John Griffin 2,230,000 sh (unchged)
Manning & Napier Advisors, Inc 288,180 sh (unchged)
Joel Greenblatt Sold Out
Paul Tudor Jones Sold Out
PRIMECAP Management 8,016,518 sh (-0.34%)
Columbia Wanger 416,200 sh (-51.25%)
Steven Cohen 74,600 sh (-88.96%)
» More
Q1 2015

BMRN Guru Trades in Q1 2015

Joel Greenblatt 4,195 sh (New)
Signature Select Canadian Fund 18,300 sh (New)
Frank Sands 12,335,452 sh (+1.25%)
PRIMECAP Management 8,025,008 sh (+0.11%)
John Griffin 2,230,000 sh (unchged)
Columbia Wanger Sold Out
Manning & Napier Advisors, Inc Sold Out
Steven Cohen Sold Out
Louis Moore Bacon 27,500 sh (-50.98%)
RS Investment Management 33,900 sh (-64.09%)
» More
Q2 2015

BMRN Guru Trades in Q2 2015

Kyle Bass 9,886 sh (New)
Paul Tudor Jones 2,062 sh (New)
Jim Simons 123,671 sh (New)
Louis Moore Bacon Sold Out
Joel Greenblatt Sold Out
PRIMECAP Management 7,992,749 sh (-0.40%)
RS Investment Management 32,570 sh (-3.92%)
RS Investment Management 32,570 sh (-3.92%)
John Griffin 2,120,000 sh (-4.93%)
Frank Sands 11,627,607 sh (-5.74%)
PRIMECAP Management 7,999,958 sh (-0.31%)
» More
» Details

Insider Trades

Latest Guru Trades with BMRN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 9.13
BMRN's P/B is ranked lower than
74% of the 751 Companies
in the Global Biotechnology industry.

( Industry Median: 4.08 vs. BMRN: 9.13 )
Ranked among companies with meaningful P/B only.
BMRN' s 10-Year P/B Range
Min: 3.68  Med: 6.91 Max: 28.5
Current: 9.13
3.68
28.5
P/S 23.70
BMRN's P/S is ranked lower than
68% of the 604 Companies
in the Global Biotechnology industry.

( Industry Median: 10.19 vs. BMRN: 23.70 )
Ranked among companies with meaningful P/S only.
BMRN' s 10-Year P/S Range
Min: 3.37  Med: 15.53 Max: 89.57
Current: 23.7
3.37
89.57
Current Ratio 3.49
BMRN's Current Ratio is ranked lower than
56% of the 833 Companies
in the Global Biotechnology industry.

( Industry Median: 4.15 vs. BMRN: 3.49 )
Ranked among companies with meaningful Current Ratio only.
BMRN' s 10-Year Current Ratio Range
Min: 0.9  Med: 6.55 Max: 18.94
Current: 3.49
0.9
18.94
Quick Ratio 2.81
BMRN's Quick Ratio is ranked lower than
60% of the 833 Companies
in the Global Biotechnology industry.

( Industry Median: 4.01 vs. BMRN: 2.81 )
Ranked among companies with meaningful Quick Ratio only.
BMRN' s 10-Year Quick Ratio Range
Min: 0.82  Med: 5.76 Max: 18.77
Current: 2.81
0.82
18.77
Days Inventory 520.22
BMRN's Days Inventory is ranked lower than
96% of the 410 Companies
in the Global Biotechnology industry.

( Industry Median: 120.98 vs. BMRN: 520.22 )
Ranked among companies with meaningful Days Inventory only.
BMRN' s 10-Year Days Inventory Range
Min: 106.92  Med: 514.36 Max: 917.29
Current: 520.22
106.92
917.29
Days Sales Outstanding 78.84
BMRN's Days Sales Outstanding is ranked lower than
61% of the 568 Companies
in the Global Biotechnology industry.

( Industry Median: 62.77 vs. BMRN: 78.84 )
Ranked among companies with meaningful Days Sales Outstanding only.
BMRN' s 10-Year Days Sales Outstanding Range
Min: 50.96  Med: 79.37 Max: 212.92
Current: 78.84
50.96
212.92

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 17.43
BMRN's Price/Tangible Book is ranked lower than
86% of the 693 Companies
in the Global Biotechnology industry.

( Industry Median: 5.31 vs. BMRN: 17.43 )
Ranked among companies with meaningful Price/Tangible Book only.
BMRN' s 10-Year Price/Tangible Book Range
Min: 2.13  Med: 7.35 Max: 111.83
Current: 17.43
2.13
111.83
Price/Projected FCF 40.60
BMRN's Price/Projected FCF is ranked lower than
91% of the 158 Companies
in the Global Biotechnology industry.

( Industry Median: 4.00 vs. BMRN: 40.60 )
Ranked among companies with meaningful Price/Projected FCF only.
BMRN' s 10-Year Price/Projected FCF Range
Min: 19.71  Med: 29.22 Max: 234.29
Current: 40.6
19.71
234.29
Price/Median PS Value 1.55
BMRN's Price/Median PS Value is ranked lower than
67% of the 544 Companies
in the Global Biotechnology industry.

( Industry Median: 1.08 vs. BMRN: 1.55 )
Ranked among companies with meaningful Price/Median PS Value only.
BMRN' s 10-Year Price/Median PS Value Range
Min: 0.26  Med: 1.18 Max: 9.94
Current: 1.55
0.26
9.94
Earnings Yield (Greenblatt) (%) -0.87
BMRN's Earnings Yield (Greenblatt) (%) is ranked higher than
69% of the 822 Companies
in the Global Biotechnology industry.

( Industry Median: -6.30 vs. BMRN: -0.87 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
BMRN' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: -0.95  Med: 1.50 Max: 3.3
Current: -0.87
-0.95
3.3

Analyst Estimate

Dec15 Dec16 Dec17
Revenue(Mil) 887 1,154 1,441
EPS($) -1.32 -1.30 0.18
EPS without NRI($) -1.32 -1.30 0.18

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:BM8.Germany,
Biomarin Pharmaceutical Inc was incorporated in Delaware on October 1996 and began operations on March 21, 1997. It develops and commercializes pharmaceuticals for serious diseases and medical conditions. The Company selects product candidates for diseases and conditions that represent an unmet medical need. Its product portfolio is comprised of five approved products and multiple investigational product candidates. Approved products include VIMIZIM (elosulfase alfa), Naglazyme (galsulfase), Kuvan (sapropterin dihydrochloride), Aldurazyme (laronidase) and Firdapse (amifampridine phosphate). The Company is conducting clinical trials on several investigational product candidates for the treatment of various diseases including PEG PAL, an enzyme substitution therapy for the treatment of PKU; BMN 701, an enzyme replacement therapy for Pompe disease, a glycogen storage disorder; BMN 673, an orally available poly-ADP ribose polymerase inhibitor for the treatment of patients with certain cancers BMN 111, a peptide therapeutic for the treatment of achondroplasia, the cause of dwarfism: and BMN 190 for the treatment of late infantile neuronal ceroid lipofuscinosis(CLN2), lysomal storage disorder affecting the brain. The Company faces competition from biological products approved through an abbreviated regulatory pathway. The Company operates in a regulated industry, which is subject to significant federal, state, local and foreign regulation.
» More Articles for BMRN

Headlines

Articles On GuruFocus.com
Medivation to Expand Global Oncology Franchise With the Acquisition of All Worldwide Rights to Talaz Aug 24 2015 
biotech 2015 Aug 20 2015 
biotech 2015 Aug 20 2015 
J.P. Morgan’s 3 Biotechnology Picks Apr 14 2015 
You Can No Longer Ignore Biotech Feb 07 2014 
Weekly Top Insider Sells: AAPL, GILD, BMRN, and PCLN Nov 19 2012 
WEEKLY CFO SELLS HIGHLIGHT: VVUS, DIS, SNPS, TXRH, BMRN Mar 04 2012 
5 Resilient Biotech Stocks to Buy for 2012 Feb 28 2012 
Weekly CFO Sells Highlight: MSCC, BMRN, VAL, CUTR, REX, CIEN Oct 02 2011 
BioMarin Pharmaceutical Inc. Reports Operating Results (10-K) Feb 24 2011 

More From Other Websites
Predicting the Outcome of the Biomarin and Sarepta FDA Drug Reviews Aug 27 2015
The Zacks Analyst Blog Highlights: Vital Therapies, Amgen, BioMarin, Acorda and Macrocure Aug 27 2015
Sarepta's DMD Drug Eteplirsen Gains FDA Priority Review Aug 26 2015
Sarepta Upgraded On Promising Muscular-Dystrophy Drug Aug 26 2015
Biotech Stock Roundup: Acorda Gains on Patent Issues, Vital Crushed by Liver Data Aug 26 2015
Sarepta gains after-hours as FDA accepts application for Duchenne drug approval Aug 25 2015
Medivation to Gain Global Rights to BioMarin's Talazoparib Aug 25 2015
BioMarin's Medivation Deal Boosts EPS Aug 25 2015
Two Bay Area drug companies cut half-billion-dollar cancer drug deal Aug 24 2015
Medivation Buying Breast-Cancer Drug From BioMarin Aug 24 2015
Medivation to Expand Global Oncology Franchise With the Acquisition of All Worldwide Rights to... Aug 24 2015
Medivation to Expand Global Oncology Franchise With the Acquisition of All Worldwide Rights to... Aug 24 2015
BIOMARIN PHARMACEUTICAL INC Files SEC form 8-K, Entry into a Material Definitive Agreement,... Aug 24 2015
Medivation to Expand Global Oncology Franchise With the Acquisition of All Worldwide Rights to... Aug 24 2015
Medivation to Expand Global Oncology Franchise With the Acquisition of All Worldwide Rights to... Aug 24 2015
UBS Analysts Might've Found Another BioMarin Catalyst Aug 21 2015
BioMarin's Drisapersen Gets Rare Pediatric Disease Status Aug 20 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK